Understand the source comparison
SS-31 vs Substrate Supplementation vs MitoQ: Research Application Comparison
SS-31 Cardiolipin stabilization, cristae preservation 30–50% No Yes Best choice for ischemia-reperfusion, acute ROS models, and aging studies where structural mitochondrial damage is the limiting factor. Does not address substrate depletion. Pyruvate/NAD+ supp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-31
- Cardiolipin stabilization, cristae preservation
- 30–50%
- No
- Yes
- Best choice for ischemia-reperfusion, acute ROS models, and aging studies where structural mitochondrial damage is the limiting factor. Does not address substrate depletion.
- Pyruvate/NAD+ supplementation
- Substrate provision for TCA cycle and electron donors
- 15–25%
- Yes (requires functional ETC)
- Effective only when substrate availability is limiting and mitochondria are structurally intact. Fails in models with cardiolipin oxidation or cristae disruption.
- MitoQ
- Mitochondria-targeted antioxidant (ubiquinone conjugate)
- 10–20%
- Yes (TPP+ cation requires Δψm)
- Partial
- Reduces ROS production but doesn't prevent cristae unfolding. Less effective than SS-31 in ischemia models but may complement SS-31 in chronic oxidative stress protocols.
- CoQ10 supplementation
- Electron carrier replenishment
- 5–15%
- Minimal benefit unless CoQ10 depletion is confirmed. Does not address structural defects or cardiolipin oxidation.
- Substrate supplementation assumes the mitochondrial machinery is functional but fuel-limited. That's rarely true in disease models. The machinery itself is damaged. SS-31 addresses the architectural failure that substrate alone can't fix.